Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Affiliations

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
² Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
³ Onkologie Ravensburg, Ravensburg, Germany.
⁴ Clinics Ostalb, Stauferklinikum, Mutlangen, Germany.
⁵ Ambulantes Krebszentrum, Frankfurt, Germany.
⁶ Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
⁷ Luebecker Onkologische Schwerpunktpraxis, Luebeck, Germany.
⁸ Überörtliche Berufsausübungsgemeinschaft, Regensburg, Germany.
⁹ Department of Internal Medicine III, Ulm University, Germany.
¹⁰ Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany.
¹¹ Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
¹² Gilead Sciences, Inc., Foster City, CA, USA.

Nadine Kutsch et al. Hemasphere. 2022.

. 2022 May 25;6(6):e729.

doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun.

¹ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German CLL Study Group, University of Cologne, Germany.
² Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Germany.
³ Onkologie Ravensburg, Ravensburg, Germany.
⁴ Clinics Ostalb, Stauferklinikum, Mutlangen, Germany.
⁵ Ambulantes Krebszentrum, Frankfurt, Germany.
⁶ Klinik für Hämatologie, Onkologie und Gastroenterologie, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
⁷ Luebecker Onkologische Schwerpunktpraxis, Luebeck, Germany.
⁸ Überörtliche Berufsausübungsgemeinschaft, Regensburg, Germany.
⁹ Department of Internal Medicine III, Ulm University, Germany.
¹⁰ Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany.
¹¹ Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.
¹² Gilead Sciences, Inc., Foster City, CA, USA.

No abstract available

References

1. Byrd JC, Brown JR, O’Brien S, et al. . Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223. - PMC - PubMed
1. Moreno C, Greil R, Demirkan F, et al. . Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56. - PubMed
1. Shanafelt TD, Wang XV, Kay NE, et al. . Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–443. - PMC - PubMed
1. Ahn IE, Farooqui MZH, Tian X, et al. . Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357–2366. - PMC - PubMed
1. Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019;14:197–205. - PubMed